Alexza Pharmaceuticals Inc. (ALXA)
-NasdaqGM 4.68 
0.23(5.17%) May 21, 4:00PM EDT
| Prev Close: | 4.45 |
|---|
| Open: | 4.41 |
|---|
| Bid: | 4.67 x 400 |
|---|
| Ask: | 4.74 x 500 |
|---|
| 1y Target Est: | 10.00 |
|---|
| Beta: | 1.46 |
|---|
| Next Earnings Date: | 9-Aug-13 |
|---|
| Day's Range: | 4.39 - 4.75 |
|---|
| 52wk Range: | 2.55 - 6.65 |
|---|
| Volume: | 719,648 |
|---|
| Avg Vol (3m): | 389,584 |
|---|
| Market Cap: | 73.99M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -3.17 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ALEXZA PHARMACEUTICALS INC. FinancialsEDGAR Online Financials(Tue, May 21)
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’at Bloomberg(Mon, May 20)
- Alexza Pharmaceuticals Has A Partner In Big Pharma, Now What?at Seeking Alpha(Wed, May 15)
- Alexza Pharmaceuticals: A Teva Partnership Of Immense Meaningat Seeking Alpha(Wed, May 15)
- Alexza Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 14)
- Alexza Pharmaceuticals, Inc. Earnings Call scheduled for 5:00 pm ET todayCCBN(Tue, May 14)
- Alexza Reports 2013 First Quarter Financial ResultsPR Newswire(Tue, May 14)
- ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements aEDGAR Online(Tue, May 14)
- Teva - Alexza Sign Deal for AdasuveZacks(Mon, May 13)
- Alexza Pharmaceuticals Earnings Preview: Get Ahead of the Analystsat Wall St. Cheat Sheet(Mon, May 13)
- Adasuve Deal Is Very Good For Alexza, But What About Teva?at Investopedia(Thu, May 9)
- Alexza Pharmaceuticals: Here’s What Investors Need to Know Before Earningsat Wall St. Cheat Sheet(Thu, May 9)
- Q1 2013 Alexza Pharmaceuticals, Inc. Earnings Release - After Market CloseCCBN(Thu, May 9)
- 3 Healthcare Stock Stories Prescribed For Investorsat Wall St. Cheat Sheet(Wed, May 8)
- Alexza Pharma jumps on Adasuve licensing dealAP(Wed, May 8)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 24.14 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.75 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.51 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide.
View More